Zacks Research Comments on Dr. Reddy’s Laboratories Limited’s FY2026 Earnings (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Zacks Research decreased their FY2026 earnings per share estimates for Dr. Reddy’s Laboratories in a report released on Tuesday, April 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $4.11 per share for the year, down from their prior forecast of $4.12. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $3.96 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. The company had revenue of $867.00 million during the quarter, compared to analyst estimates of $827.81 million.

RDY has been the subject of a number of other reports. Jefferies Financial Group lowered Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a report on Thursday, January 11th. Barclays boosted their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. Finally, StockNews.com upgraded Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 5th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $80.00.

Dr. Reddy’s Laboratories Stock Down 0.5 %

Shares of RDY stock opened at $70.92 on Wednesday. Dr. Reddy’s Laboratories has a 12 month low of $53.12 and a 12 month high of $77.72. The firm has a market cap of $11.84 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. The stock has a 50 day moving average of $74.50 and a 200-day moving average of $70.17. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02.

Institutional Trading of Dr. Reddy’s Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of RDY. Bank of New York Mellon Corp increased its position in shares of Dr. Reddy’s Laboratories by 982.0% during the first quarter. Bank of New York Mellon Corp now owns 78,249 shares of the company’s stock valued at $4,361,000 after purchasing an additional 71,017 shares during the period. American Century Companies Inc. grew its position in Dr. Reddy’s Laboratories by 49.8% in the first quarter. American Century Companies Inc. now owns 28,203 shares of the company’s stock valued at $1,572,000 after acquiring an additional 9,382 shares during the period. US Bancorp DE grew its position in Dr. Reddy’s Laboratories by 14.1% in the first quarter. US Bancorp DE now owns 11,725 shares of the company’s stock valued at $653,000 after acquiring an additional 1,452 shares during the period. Citigroup Inc. grew its position in Dr. Reddy’s Laboratories by 29.8% in the first quarter. Citigroup Inc. now owns 12,892 shares of the company’s stock valued at $718,000 after acquiring an additional 2,958 shares during the period. Finally, BlackRock Inc. grew its position in Dr. Reddy’s Laboratories by 2.0% in the first quarter. BlackRock Inc. now owns 1,583,891 shares of the company’s stock valued at $88,271,000 after acquiring an additional 30,341 shares during the period. 14.02% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.